563 related articles for article (PubMed ID: 18073307)
1. Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study.
Elisei R; Cosci B; Romei C; Bottici V; Renzini G; Molinaro E; Agate L; Vivaldi A; Faviana P; Basolo F; Miccoli P; Berti P; Pacini F; Pinchera A
J Clin Endocrinol Metab; 2008 Mar; 93(3):682-7. PubMed ID: 18073307
[TBL] [Abstract][Full Text] [Related]
2. Somatic mutations in the RET proto-oncogene in sporadic medullary thyroid carcinomas.
Dvorakova S; Vaclavikova E; Sykorova V; Vcelak J; Novak Z; Duskova J; Ryska A; Laco J; Cap J; Kodetova D; Kodet R; Krskova L; Vlcek P; Astl J; Vesely D; Bendlova B
Mol Cell Endocrinol; 2008 Mar; 284(1-2):21-7. PubMed ID: 18282654
[TBL] [Abstract][Full Text] [Related]
3. Combined RET and Ki-67 assessment in sporadic medullary thyroid carcinoma: a useful tool for patient risk stratification.
Mian C; Pennelli G; Barollo S; Cavedon E; Nacamulli D; Vianello F; Negro I; Pozza G; Boschin IM; Pelizzo MR; Rugge M; Mantero F; Girelli ME; Opocher G
Eur J Endocrinol; 2011 Jun; 164(6):971-6. PubMed ID: 21422198
[TBL] [Abstract][Full Text] [Related]
4. Role of CDKN2C Copy Number in Sporadic Medullary Thyroid Carcinoma.
Grubbs EG; Williams MD; Scheet P; Vattathil S; Perrier ND; Lee JE; Gagel RF; Hai T; Feng L; Cabanillas ME; Cote GJ
Thyroid; 2016 Nov; 26(11):1553-1562. PubMed ID: 27610696
[TBL] [Abstract][Full Text] [Related]
5. Low prevalence of the somatic M918T RET mutation in micro-medullary thyroid cancer.
Romei C; Ugolini C; Cosci B; Torregrossa L; Vivaldi A; Ciampi R; Tacito A; Basolo F; Materazzi G; Miccoli P; Vitti P; Pinchera A; Elisei R
Thyroid; 2012 May; 22(5):476-81. PubMed ID: 22404432
[TBL] [Abstract][Full Text] [Related]
6. Chromosome 10 and RET gene copy number alterations in hereditary and sporadic Medullary Thyroid Carcinoma.
Ciampi R; Romei C; Cosci B; Vivaldi A; Bottici V; Renzini G; Ugolini C; Tacito A; Basolo F; Pinchera A; Elisei R
Mol Cell Endocrinol; 2012 Jan; 348(1):176-82. PubMed ID: 21867742
[TBL] [Abstract][Full Text] [Related]
7. Evidence of a low prevalence of RAS mutations in a large medullary thyroid cancer series.
Ciampi R; Mian C; Fugazzola L; Cosci B; Romei C; Barollo S; Cirello V; Bottici V; Marconcini G; Rosa PM; Borrello MG; Basolo F; Ugolini C; Materazzi G; Pinchera A; Elisei R
Thyroid; 2013 Jan; 23(1):50-7. PubMed ID: 23240926
[TBL] [Abstract][Full Text] [Related]
8. New multiple somatic mutations in the RET proto-oncogene associated with a sporadic medullary thyroid carcinoma.
Dvoráková S; Václavíková E; Sýkorová V; Dusková J; Vlcek P; Ryska A; Novák Z; Bendlová B
Thyroid; 2006 Mar; 16(3):311-6. PubMed ID: 16571096
[TBL] [Abstract][Full Text] [Related]
9. RET genetic screening in patients with medullary thyroid cancer and their relatives: experience with 807 individuals at one center.
Elisei R; Romei C; Cosci B; Agate L; Bottici V; Molinaro E; Sculli M; Miccoli P; Basolo F; Grasso L; Pacini F; Pinchera A
J Clin Endocrinol Metab; 2007 Dec; 92(12):4725-9. PubMed ID: 17895320
[TBL] [Abstract][Full Text] [Related]
10. Somatic mutations in the RET proto-oncogene in sporadic medullary thyroid carcinoma.
Marsh DJ; Learoyd DL; Andrew SD; Krishnan L; Pojer R; Richardson AL; Delbridge L; Eng C; Robinson BG
Clin Endocrinol (Oxf); 1996 Mar; 44(3):249-57. PubMed ID: 8729519
[TBL] [Abstract][Full Text] [Related]
11. Classical point mutations of RET, BRAF and RAS oncogenes are not shared in papillary and medullary thyroid cancer occurring simultaneously in the same gland.
Ciampi R; Romei C; Pieruzzi L; Tacito A; Molinaro E; Agate L; Bottici V; Casella F; Ugolini C; Materazzi G; Basolo F; Elisei R
J Endocrinol Invest; 2017 Jan; 40(1):55-62. PubMed ID: 27535135
[TBL] [Abstract][Full Text] [Related]
12. High prevalence of RAS mutations in RET-negative sporadic medullary thyroid carcinomas.
Moura MM; Cavaco BM; Pinto AE; Leite V
J Clin Endocrinol Metab; 2011 May; 96(5):E863-8. PubMed ID: 21325462
[TBL] [Abstract][Full Text] [Related]
13. CGH alterations in medullary thyroid carcinomas in relation to the RET M918T mutation and clinical outcome.
Frisk T; Zedenius J; Lundberg J; Wallin G; Kytölä S; Larsson C
Int J Oncol; 2001 Jun; 18(6):1219-25. PubMed ID: 11351254
[TBL] [Abstract][Full Text] [Related]
14. Mutational screening of RET, HRAS, KRAS, NRAS, BRAF, AKT1, and CTNNB1 in medullary thyroid carcinoma.
Schulten HJ; Al-Maghrabi J; Al-Ghamdi K; Salama S; Al-Muhayawi S; Chaudhary A; Hamour O; Abuzenadah A; Gari M; Al-Qahtani M
Anticancer Res; 2011 Dec; 31(12):4179-83. PubMed ID: 22199277
[TBL] [Abstract][Full Text] [Related]
15. Tumor Grade and Molecular Characteristics Associated with Survival in Sporadic Medullary Thyroid Carcinoma.
Censi S; Galuppini F; Clausi C; Battheu F; Manso J; Piva I; Corvaglia S; Pedron MC; Mondin A; Iacobone M; Torresan F; Merante Boschin I; Bertazza L; Barollo S; Pennelli G; Mian C
Thyroid; 2024 Feb; 34(2):177-185. PubMed ID: 38047536
[No Abstract] [Full Text] [Related]
16. RET exon 11 (G691S) polymorphism is significantly more frequent in sporadic medullary thyroid carcinoma than in the general population.
Elisei R; Cosci B; Romei C; Bottici V; Sculli M; Lari R; Barale R; Pacini F; Pinchera A
J Clin Endocrinol Metab; 2004 Jul; 89(7):3579-84. PubMed ID: 15240649
[TBL] [Abstract][Full Text] [Related]
17. Somatic RAS mutations occur in a large proportion of sporadic RET-negative medullary thyroid carcinomas and extend to a previously unidentified exon.
Boichard A; Croux L; Al Ghuzlan A; Broutin S; Dupuy C; Leboulleux S; Schlumberger M; Bidart JM; Lacroix L
J Clin Endocrinol Metab; 2012 Oct; 97(10):E2031-5. PubMed ID: 22865907
[TBL] [Abstract][Full Text] [Related]
18. Influence of RET mutations on the expression of tyrosine kinases in medullary thyroid carcinoma.
Rodríguez-Antona C; Muñoz-Repeto I; Inglada-Pérez L; de Cubas AA; Mancikova V; Cañamero M; Maliszewska A; Gómez A; Letón R; Leandro-García LJ; Comino-Méndez I; Sanchez L; Alvarez-Escolá C; Aller J; Cascón A; Robledo M
Endocr Relat Cancer; 2013 Aug; 20(4):611-9. PubMed ID: 23780998
[TBL] [Abstract][Full Text] [Related]
19. Prognostic Significance of Circulating RET M918T Mutated Tumor DNA in Patients With Advanced Medullary Thyroid Carcinoma.
Cote GJ; Evers C; Hu MI; Grubbs EG; Williams MD; Hai T; Duose DY; Houston MR; Bui JH; Mehrotra M; Waguespack SG; Busaidy NL; Cabanillas ME; Habra MA; Luthra R; Sherman SI
J Clin Endocrinol Metab; 2017 Sep; 102(9):3591-3599. PubMed ID: 28911154
[TBL] [Abstract][Full Text] [Related]
20. A cohort study on 10-year survival of sporadic medullary thyroid carcinoma with somatic RET mutation.
Chuang LL; Hwang DY; Tsai KB; Chan HM; Chiang FY; Hsiao PJ
Kaohsiung J Med Sci; 2016 Nov; 32(11):545-551. PubMed ID: 27847096
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
